Subscribe to the BioNews newsletter for free

Advanced Search

Search for

Like the Progress Educational Trust on Facebook



Liquid DNA biopsies could be used for cancer screening

21 August 2017

By Dr Loredana Guglielmi

Appeared in BioNews 914

US researchers have developed a new blood test to detect cancer-related DNA alterations before patients experience symptoms.

The test, known as liquid biopsy, correctly identified over half of patients with early stage cancers and produced no false positives. The diagnostic accuracy of the test increased in later disease stages. 

'This is one of the first studies to use an unbiased approach - you don't know where the mutations are going to be - and to look at the blood of early-stage cancer patients to see whether we could detect alterations,' said Professor Victor Velculescu, who led the study at the Johns Hopkins Kimmel Cancer Centre, Maryland. 

The study evaluated the presence of fragments of tumour DNA (cfDNA) in the blood of 200 patients with colorectal breast, lung, and ovarian cancers compared to a control group of 44 healthy donors.

Previous studies using liquid biopsies have been used to detect cancer relapse or to determine whether treatments are working. In those cases the specific mutation in a particular patient's cancer are known, and can be targeted.

In the new study, published in Science Translational Medicine, a panel of 58 cancer-associated genes was used to screen all the blood samples with a new technology called targeted error correction sequencing (TEC-seq) which sequences the fragments of DNA 30,000 times. The test is sensitive enough to differentiate DNA modifications which normally occur from cancer driver mutations during an individual's life.

'It's actually very hard to find these mutations in the blood, especially when you don't know what the mutations are upfront,' commented Professor Velculescu. 'There are a number of confounding errors that can come up. Besides sequencing and technical errors, you can get alterations that come from the germline and can also get mutations that come from blood cells. We developed a way in which you could distinguish tumour driver mutations from these other alterations that might be in the blood.'

Next steps for the team are to increase the number of patients and type of cancers screened, and conduct clinical trials to assess the new technology impact on clinical outcomes. Such deep sequencing analyses are currently too costly to be implemented as routine diagnostic tools.

NBC News | 17 August 2017
Science Translational Medicine | 16 August 2017
Medpage Today | 16 August 2017
Johns Hopkins Medicine | 16 August 2017


06 November 2017 - by Isobel Steer 
Machine learning has been used to develop a promising screening test for ovarian cancer, a team of US-based researchers has said...

26 June 2017 - by Charlotte Spicer 
A new three-in-one blood test could progress personalised treatment for patients with prostate cancer...
02 May 2017 - by Dr Loredana Guglielmi 
Blood tests for tumour DNA could predict relapse of the most common type of lung cancer up to one year before clinical signs show up on patient's scans...
13 March 2017 - by Dr Loredana Guglielmi 
Researchers have developed a new blood test that can not only detect cancer at an early stage, but can also indicate where the tumour is located in the body...
09 November 2015 - by Ayala Ochert 
Scientists say it may be possible to track the progress of cancer – and cancer treatment – in real time from fragments of tumour DNA that are shed into the bloodstream...

Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

- click here to enquire about using this story.

Published by the Progress Educational Trust


Public Conference
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation